MDA
VRTX icon

Minot DeBlois Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Minot DeBlois Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.97K Hold
10
– – ﹤0.01% 165
2026
Q1 		$4.46K Hold
10
– – ﹤0.01% 162
2025
Q4 		$4.53K Hold
10
– – ﹤0.01% 159
2025
Q3 		$3.92K Hold
10
– – ﹤0.01% 199
2025
Q2 		$4.45K Hold
10
– – ﹤0.01% 207
2025
Q1 		$4.85K Sell
10
-100
-91% -$46.6K ﹤0.01% 198
2024
Q4 		$44.3K Buy
+110
New +$51K 0.04% 127

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Minot DeBlois Advisors's VRTX Position: Q2 2026 in Review

Minot DeBlois Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 10 shares worth $4.97K. The position accounts for ﹤0.01% of the portfolio, ranked #165.

Minot DeBlois Advisors first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $44.3K in Q4 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Minot DeBlois Advisors held 10 shares of Vertex Pharmaceuticals worth $4.97K as of Q2 2026.
  • Minot DeBlois Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Minot DeBlois Advisors's portfolio in Q2 2026, its #165 holding.
  • Minot DeBlois Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Minot DeBlois Advisors's Vertex Pharmaceuticals position peaked at $44.3K in Q4 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Minot DeBlois Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.